Among these are three inactivated vaccines and one adenovirus vector vaccine in phase-three trials overseas.
The Beijing Institute of Biotechnology and biotech company CanSino Biologics are jointly developing the adenovirus vector vaccine.
While influenza and rhinovirus are the most prevalent among toddlers aged 1 to 4, for children aged 5 to 14, influenza, mycoplasma pneumoniae and adenovirus are common infections, Wang Huaqing, chief immunization planning expert at the Chinese Center for Disease Control and Prevention, said during a recent news conference.
These kits target several viruses — type A influenza virus, type B influenza virus, mycoplasma pneumonia virus and adenovirus.
The point-of-care testing-based polymerase chain reaction technique detects 18 types of respiratory microbes, including type A and type B influenza viruses, adenovirus, rhinovirus, respiratory syncytial virus and others, all at once.
Yang Xiaoming, president of CNBG, said that currently, there are more than 100 research institutions worldwide working on vaccines targeting COVID-19, and the vaccines can be classified into roughly five types-inactivated vaccine, gene recombinant vaccine, adenovirus vaccine, viral vector vaccine, and nucleic acid vaccine.
Eric Rubin, an infectious disease expert and editor-in-chief of the New England Journal of Medicine, a leading global medical journal, said although there are promising advancements in utilizing DNA and adenovirus to develop a vaccine, further clinical trials are required to better assess if they are effective and safe for human consumption.